Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke
- PMID: 32933416
- DOI: 10.1161/STROKEAHA.120.029994
Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke
Abstract
Background and purpose: This study aimed to evaluate the treatment effect of intraarterial versus intravenous tirofiban during endovascular thrombectomy in acute ischemic stroke.
Methods: This study retrospectively examined 503 patients with acute ischemic stroke with large vessel occlusion who received endovascular thrombectomy within 24 hours of stroke onset. Patients were divided into 3 groups: no tirofiban (n=354), intraarterial tirofiban (n=79), and intravenous tirofiban (n=70). The 3 groups were compared in terms of recanalization rate, symptomatic intracerebral hemorrhage, in-hospital death rate, 3-month death, and 3-month outcomes measured by modified Rankin Scale score (good clinical outcome of 0-2, poor outcome of 5-6). The comparison was statistically assessed by propensity score matching, followed by Freidman rank-sum test and pairwise Wilcoxon signed-rank test with Bonferroni correction.
Results: The propensity score matching resulted in 92 matched triplets. Compared with the no-tirofiban group, the intravenous tirofiban group showed significantly increased recanalization (96.7% versus 64.1%, P<0.001), an increased rate of 3-month good outcome (69.5% versus 51.2%, P=0.034), and a lower rate of 3-month poor outcome (12.2% versus 41.4%, P<0.001). There was no significant difference between the tirofiban intravenous and no-tirofiban groups in terms of symptomatic intracerebral hemorrhage (2.2% versus 0%, P=1.000). However, symptomatic intracerebral hemorrhage was significantly increased in the intraarterial-tirofiban group compared with the no-tirofiban group (19.1% versus 0%, P<0.001), with an increased rate of in-hospital death (23.6% versus 0% P<0.001), and increased rate of 3-month death (26.8% versus 11.1%, P=0.021). The intraarterial-tirofiban and no-tirofiban group showed no significant difference in recanalization rate (66.3% versus 64.1%, P=1.000).
Conclusions: As an adjunct to endovascular thrombectomy, intravenous tirofiban is associated with high recanalization rate and good outcome, whereas intraarterial tirofiban is associated with high hemorrhagic rate and death rate.
Keywords: atherosclerosis; death; hemorrhage; stroke; thrombectomy; tirofiban.
Similar articles
-
The Efficacy and Safety of Tirofiban Use in Endovascular Thrombectomy for Intravenous Thrombolysis Applicable Patients with Large Vessel Occlusion Stroke-a Post Hoc Analysis from the Direct-MT Trial.Cardiovasc Intervent Radiol. 2024 Feb;47(2):208-215. doi: 10.1007/s00270-023-03540-9. Epub 2023 Oct 5. Cardiovasc Intervent Radiol. 2024. PMID: 37798430 Free PMC article.
-
Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry.J Am Heart Assoc. 2024 Mar 5;13(5):e032326. doi: 10.1161/JAHA.123.032326. Epub 2024 Feb 23. J Am Heart Assoc. 2024. PMID: 38390817 Free PMC article.
-
Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.JAMA. 2022 Aug 9;328(6):543-553. doi: 10.1001/jama.2022.12584. JAMA. 2022. PMID: 35943471 Free PMC article. Clinical Trial.
-
Meta-analysis of the efficacy and safety of tirofiban in patients with acute ischaemic stroke undergoing mechanical thrombectomy.Clin Neurol Neurosurg. 2023 May;228:107702. doi: 10.1016/j.clineuro.2023.107702. Epub 2023 Mar 28. Clin Neurol Neurosurg. 2023. PMID: 37058772 Review.
-
Is bridging with intravenous thrombolysis of any benefit in endovascular therapy for acute ischemic stroke?World Neurosurg. 2014 Sep-Oct;82(3-4):e453-8. doi: 10.1016/j.wneu.2013.01.097. Epub 2013 Feb 1. World Neurosurg. 2014. PMID: 23376392 Review.
Cited by
-
Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial.Eur J Med Res. 2023 Nov 1;28(1):473. doi: 10.1186/s40001-023-01406-x. Eur J Med Res. 2023. PMID: 37915101 Free PMC article. Clinical Trial.
-
The Efficacy and Safety of Tirofiban Use in Endovascular Thrombectomy for Intravenous Thrombolysis Applicable Patients with Large Vessel Occlusion Stroke-a Post Hoc Analysis from the Direct-MT Trial.Cardiovasc Intervent Radiol. 2024 Feb;47(2):208-215. doi: 10.1007/s00270-023-03540-9. Epub 2023 Oct 5. Cardiovasc Intervent Radiol. 2024. PMID: 37798430 Free PMC article.
-
The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis.AJNR Am J Neuroradiol. 2021 Sep;42(9):1633-1637. doi: 10.3174/ajnr.A7203. Epub 2021 Jul 22. AJNR Am J Neuroradiol. 2021. PMID: 34301637 Free PMC article.
-
Efficacy and safety of tirofiban in patients with acute branch atheromatous disease-related stroke (BRANT): a protocol for a randomised controlled trial.BMJ Open. 2024 Jun 10;14(6):e082141. doi: 10.1136/bmjopen-2023-082141. BMJ Open. 2024. PMID: 38858147 Free PMC article.
-
Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis.Front Neurol. 2022 Oct 4;13:982684. doi: 10.3389/fneur.2022.982684. eCollection 2022. Front Neurol. 2022. PMID: 36267890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials